Maximilian Diehn, MD, PhD

Maximilian Diehn is a cofounder of Foresight Diagnostics and Professor of Radiation Oncology, Vice Chair of Research, and Division Chief of Radiation and Cancer Biology at Stanford University. Maximilian has a long track record of research accomplishments in the fields of cancer genomics and cancer biology. His prior work focused on gene expression profiling of solid tumors and treatment resistance. More recently, and in close collaboration with Dr. Ash Alizadeh’s group, his laboratory has developed novel liquid biopsy methods for the detection of ctDNA. Currently, his research is focused on developing and applying liquid biopsy approaches to early detection, MRD, treatment response monitoring, and analysis of tumor heterogeneity. Clinically, Maximilian specializes in the treatment of lung cancer. He also manages a broad clinical research portfolio that includes multiple investigator-initiated clinical trials focused on improving personalized therapy for patients with lung cancer, including through the application of liquid biopsies.